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ScienceDirectThe DNA damage response (DDR) orchestrates DNA repair and
halts cell cycle. If damage is not resolved, cells can enter into an
irreversible state of proliferative arrest called cellular
senescence. Organismal ageing in mammals is associated with
accumulation of markers of cellular senescence and DDR
persistence at telomeres. Since the vast majority of the cells in
mammals are non-proliferating, how do they age? Are
telomeres involved? Also oncogene activation causes cellular
senescence due to altered DNA replication and DDR activation
in particular at the telomeres. Is there a common mechanism
shared among apparently distinct types of cellular
senescence? And what is the role of telomeric DNA damage?
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Introduction
Genome integrity is preserved by the DNA damage
response (DDR) that, in the presence of DNA
damage, arrests the cell cycle progression while coor-
dinating DNA repair events [1]. The DDR pathway is
composed of a complex protein network, regulated
mainly by post-translational  modifications such aswww.sciencedirect.com phosphorylation, ubiquitylation, SUMOylation, acety-
lation and PARylation [1]. Recently a direct role of
small non-coding RNAs in DDR modulation has also
been proposed [2,3]. Among the different types of
damage, DNA double-strand breaks (DSBs) are con-
sidered the most deleterious, because they can cause
cell death, a permanent proliferative arrest termed
cellular senescence  or, in checkpoint-impaired cells,
genomic instability leading to cancer development.
DSBs are repaired by two major mechanisms, the
homologous recombination (HR) pathway, an error-free
mechanism that uses a homologous chromosome as
template for repair [4], and the non-homologous end
joining (NHEJ) pathway in which the two DNA ends
are ligated together with no need for homologous
sequences [5]. If unrepaired, DNA damage fuels per-
sistent DDR signalling and cellular senescence estab-
lishment. Which kind of DNA damages is refractory to
DNA repair and triggers a permanent cell cycle arrest
was not clear until recently. An example of terminal
arrest was first observed by Hayflick and Moorhead in
1961, who reported that normal human cells in culture
can undergo only a limited number of population
doublings and eventually stop proliferating [6]. This
was later explained by the so-called end replication
problem, the inability of most normal cells to comple-
tely replicate linear genomes thus causing progressive
shortening of chromosome ends, the telomeres, at every
cell division [7]. When telomeres become critically
short, they are sensed as damaged DNA, which triggers
a DDR-initiated cellular senescence [8–10]. Despite
the fact that chromosomes bear ends that resemble a
DNA discontinuity such as a DSB, telomeres are gener-
ally not recognized as DSBs and do not activate a DDR.
This is achieved by the joint action of different telo-
mere-binding proteins, collectively named as a shel-
terin complex [11,12]. It is becoming evident that there
is a key role of telomeres in DDR modulation that is
not restricted to their shortening. In this review we will
dissect the impact of telomeric DNA damage on differ-
ent types of cellular senescence.
Replicative senescence in ageing
In the past years, a strong link between telomere-
initiated cellular senescence and organismal ageing
has emerged [13]. Evidence that cellular senescence
is a biologically active response in tissue has been foundCurrent Opinion in Genetics & Development 2014, 26:89–95
90 Molecular and genetic bases of diseasein mouse stem and somatic cells as well as in baboon and
human skin fibroblasts [14–19]. These senescent cells
are thought to contribute to tissue ageing by at least two
mechanisms. First of all intrinsically, by their inability to
further proliferate and thus to replenish tissues with new
cells; secondly, by up-regulating genes that encode
extracellular-matrix-degrading enzymes, inflammatory
cytokines and growth factors [20,21]. These secreted
factors, which are responsible for the senescent-associ-
ated secretory phenotype (SASP), act also on the neigh-
bouring cells [22,23], and fuelling DDR by still ill-
defined mechanisms [24]. The association between cel-
lular senescence and tissue ageing seems to be causa-
tive, since lack of p16, which precludes senescence
establishment, prevents the age-related decline,
thereby increasing healthspan [25–27]. Similarly, clear-
ance of p16-expressing cells leads to a delay in age-
related pathologies and to attenuation  of established
age-related disorders [28]. Telomeres seem to play a
fundamental role in senescence-mediated organismal
ageing. Indeed dysfunctional telomeres have been
found in senescent cells in vivo in primates [16,29],
and loss of telomerase function in mice causes senes-
cence and physiological impairment of many tissues
[30–33]. Moreover deletion of p21 in telomerase-
deficient mice with dysfunctional telomeres prolongs
the lifespan [34]. Telomere shortening seems to be the
driving force, since elongation of telomeres by reactiva-
tion of telomerase is sufficient to eliminate the degen-
erative phenotypes in multiple organs observed in
telomerase knock out mice [35].Figure 1
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proliferating compartments
Telomere-initiated cellular senescence seems to be a plaus-
ible mechanism to explain the ageing-associated functional
decline of proliferating tissues in vivo. However, it is reason-
able to assume that some other mechanisms may be in place
in non-proliferating cells in which no telomeric attrition due
to the end replication problem is expected to occur, either
because these cells are quiescent or differentiated. Surpris-
ingly however, we and others have shown that telomeres
might have a central role in senescence establishment
independently from their shortening [36,37]. In these
reports, random DNA damage generated by ionizing radi-
ation, genotoxic drugs, or H2O2, leads to DDR activation
that preferentially persists at telomeres over time. Cells with
persistent DDR activation show a senescent phenotype that
cannot be prevented by exogenous expression of telomer-
ase, further excluding a contribution of telomere shortening.
The mechanism proposed to explain this phenomenon is
the suppression of effective DNA repair at telomeres by
TRF2, a telomeric DNA binding protein [36]. Inhibition
of DNA repair might reflect the evolutionary role of telo-
meres in preventing chromosomal fusions, illegitimate
DNA repair events among chromosome ends, in order to
maintain the linear structure of chromosomes. TRF2 and
the associated RAP1 protein are indeed able to inhibit
NHEJ in vitro [38,39,40] and knock out of TRF2 leads to
dramatic chromosomal fusions [41,42], most of which
depend on NHEJ [43]. Similarly, TRF2 has been shown
to inhibit NHEJ also when a DSB occurs within a telomere,
and not only at its end (Figure 1), revealing that telomericl fusion)
NHEJ
Telomere
5’ TRF2 TRF2 TRF2 TRF2 3’
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event repair of DSBs (by NHEJ) occurred within telomeric repeats across
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telomere irreparability. Consistent with this model, DDR
activation at telomeres is more frequent in mouse and
baboon tissues from aged animals, when compared with
their young counterparts [36,37]. This observation also
suggests that having long telomeres may have an important
drawback, since more telomeric DNA can offer a wider
target for random DNA damage that cannot be repaired.
Indeed, in different mammalian species, telomere length
and lifespan are inversely correlated [44].
Telomeric DNA damage in oncogene-induced
senescence
In addition to its potential role in promoting ageing and
age related disorders, telomere-initiated senescence,
fuelled by oncogenic signals, plays a prominent role in
suppressing malignant cancer progression in humans. In
cells with functional DDR, oncogene expression usually
results in cellular senescence after just a few population
doublings [45]. This proliferative arrest is called onco-
gene-induced senescence (OIS) and, depending on cell
type and oncogene expression levels, is caused by acti-
vation of a number of diverse pathways [46]. Thus, by
preventing cancer onset, in addition to causing impair-
ment of regenerative capacity during ageing, cellular
senescence has been considered as an example of
antagonistic pleiotropy, although this has recently put
to question [47]. In some human cells, oncogene expres-
sion initially causes cells to hyper-proliferate, which leads
to aberrantly increased DNA replication rates causing
frequent DNA replication fork stalling events. As a con-
sequence of this, DSBs are generated in the vicinity of
collapsed replication forks and this activates a DDR and
forces cells to undergo senescence [48,49]. OIS not only
functions as a tumour suppressing mechanism in animal
model systems [50], but also cells with features of OIS,
including abundant DDR foci formation, have been
detected in a number of distinct benign neoplastic lesions
in humans and not in the corresponding malignant can-
cers [51,52,53,54]. Given that initiation of aberrant
cell proliferation in human tissues is often associated with
oncogenic events, these data are strong evidence that OIS
also suppresses cancer progression in humans.
Some chromosomal loci, called common fragile sites
(CFS), appear to be hot-spots for DSB formation as a
result of DNA replication stress. These sites are usually
repetitive in nature and have a tendency to form second-
ary structures that can impede replication fork pro-
gression [55]. In addition, CFS belong to chromosomal
regions poor of replication origins and thus unable to cope
with stalled DNA replication forks [56]. Because of their
repetitive nature, sensitivity to oxidative damage, and
propensity to form secondary structures (called G quad-
ruplexes), telomeres also pose a challenge to the replica-
tion machinery. In fact, telomeres share many other
features of CFS [57,58]. Not too surprisingly, therefore,www.sciencedirect.com recent results demonstrated that oncogene expression
leads to DNA replication stress, replication fork stalling,
and formation of DDR foci at increased rates at telomeres
[54]. However, non-telomeric DDR foci are also gener-
ated but are resolved over a period of several days in
arrested oncogene-expressing cells. These telomeric
DDR foci persist suggesting that also oncogene-induced
telomeric lesions are not efficiently repaired. Does the
persistence of the telomeric DDR foci cause oncogene-
expressing cells to arrest stably? In support of this, over-
expression of catalytically active telomerase prevents
formation of telomeric DDR foci as a result of onco-
gene-induced and drug-induced DNA replication stres-
ses. Consequently, telomerase destabilizes the
proliferative arrest caused by aberrant oncogene signal-
ling [54]. Thus, OIS is a cellular stress response that can
be enforced by telomere dysfunction.
Persistent telomeric DDR foci, or dysfunctional telo-
meres, can also be observed in most cells of benign human
neoplasias and cancer precursor lesions before telomeres
have become eroded. Foci form below a critical telomere
length in most cells of benign human neoplasias and
cancer precursor lesions such as melanocytic nevi, ductal
breast hyperplasias, and colonic adenomas [54]. Indeed,
dysfunctional telomeres in cells comprising these benign
lesions on average are not shorter compared to other
telomeres in the same cells, supporting this conclusion.
The irreparability of telomeric DSBs in this context
might therefore act as cellular sensor of hyperproliferative
signals. In cells expressing telomerase, such as those of
invasive human cancers, we would anticipate that repli-
cation stresses would not result in telomeric DDR acti-
vation. Rather, they would and allow continuous cell
proliferation. It is therefore likely that cancer cells re-
activate telomerase expression not only to prevent telo-
mere erosion, but also to cope with telomeric replication
stress that would halt cell proliferation.
Irreparability of telomeres is evolutionary
conserved in eukaryotes
The inherent characteristic of telomeres to be resistant to
DNA repair is conserved in the yeast Saccharomyces cer-
evisiae and Schizoccharomyces pombe, whose natural
chromosome ends do not join with each other or with
random DNA breaks [59–62]. Indeed, in a genetic system
in S. cerevisiae, an endonuclease-induced DSB is gener-
ated immediately adjacent to a relatively short array of
telomeric DNA repeats. The break inhibits the recruit-
ment of DNA ligase IV and therefore prevents fusions by
NHEJ [36]. The presence of telomeric sequences at
DNA ends can also prevent repair by HR, because it
limits nucleolytic degradation and therefore the gener-
ation of single-stranded DNA (ssDNA). Moreover, it
weakens the signalling activity of the Mec1 checkpoint
kinase (ATR in mammals) [63,64], which is recruited to
RPA-coated ssDNA [65]. Interestingly, this phenomenonCurrent Opinion in Genetics & Development 2014, 26:89–95
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nearby DSB devoid of telomeric repeats, but not from a
DSB present on a different chromosome [63,64].
In budding yeast, the ability of telomeric ends to resist
NHEJ-mediated repair and nucleolytic degradation
depends on at least three different protein complexes,
which are conserved from yeast to mammals. One of them
is the CST (Cdc13–Stn1–Ten1) complex, which binds to
the telomeric single-stranded overhang and prevents
nucleolytic degradation and therefore checkpoint acti-
vation at telomeres [66,67]. A second complex, the Ku70-
Ku80 heterodimer, blocks ssDNA formation specifically
in the G1 phase of the cell cycle by inhibiting the action of
the exonuclease Exo1 [68–70]. Finally, NHEJ inhibition
at telomeres is controlled primarily by the Rap1 protein,
which binds to the telomeric double-stranded DNA [71].
Rap1 prevents NHEJ by establishing two parallel inhibi-
tory pathways through its interacting proteins Rif2 and
Sir4 [72]. While it is currently unclear how these proteins
prevent NHEJ, the observations that DSBs flanked by
telomeric repeats show reduced DNA ligase IV binding
[36] suggest that they might function by counteracting
the loading of NHEJ proteins. It has been recently shown
that maintenance of NHEJ inhibition by Rap1 requires
Uls1, which is both a Swi2/Snf2-related translocase and a
Small Ubiquitin-related Modifier (SUMO)-TargetedFigure 2
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organismal levels. DNA damage at telomeres cannot be repaired, independe
shortening, replication stress) or exogenously (i.e. X-rays). Irreparable telomer
but also with oncogene-induced and DNA damage-induced cellular senescen
side, cause impairment of regenerative capacity during ageing both in prolifer
Current Opinion in Genetics & Development 2014, 26:89–95 Ubiquitin Ligase [73]. Uls1 requirement is alleviated
by inhibiting formation of SUMO chains and by rap1
mutations altering SUMOylation sites. Furthermore,
Uls1 limits the accumulation of Rap1 poly-SUMO con-
jugates, suggesting that Uls1 ensures the efficiency of
NHEJ inhibition by eliminating non-functional poly-
SUMOylated Rap1 molecules from telomeres.
Removal of telomerase causes replicative senescence
also in S. cerevisiae [74]. Interestingly, the presence
of a single critically short telomere accelerates senes-
cence in a telomerase-negative context [75,76],
suggesting that the length of the shortest telomere is a
major determinant of the onset of senescence  in this
organism. The Mec1 checkpoint kinase is required for
the accelerated loss of viability in the presence of a short
telomere [75], indicating that, like in human fibroblasts,
DDR is activated at the shortest telomere in cells under-
going senescence.
Conclusions
On the basis of the results described in this review, we can
propose a unifying model, according to which telomeres
play an essential role not only in replicative but also in
DNA damage-induced and oncogene-induced cellular
senescence (Figure 2). This provides a mechanism for
DDR-mediated and senescence-mediated ageing of non-ctivation
 stress
 DNA damage
duced
ce
DD-induced
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r Ageing
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induced and oncogene-induced senescence both at cellular and
ntly from the source that generated it, both endogenously (i.e. telomere
es are, therefore, associated not only with replicative cellular senescence
ce. These events prevent cancer onset on the one side, but on the other
ating and non-proliferating tissues at organismal level. DD, DNA damage.
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by telomeric shortening.
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